

Amikacin

Section

Antituberculosis medicines

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Access group antibiotics

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

Multi-drug resistant Mycobacterium tuberculosis

Premier choix

Neutropenia (high-risk)

co-prescrire avec cefotaxime

Inflammatory and other diseases of prostate (severe)

co-prescrire avec cefotaxime

Acute pyelonephritis (severe)

co-prescrire avec ceftriaxone

Inflammatory and other diseases of prostate (severe)

co-prescrire avec ceftriaxone

Acute pyelonephritis (severe)

Second choix

co-prescrire avec cloxacillin

Sepsis without septic shock

Amoxicillin

Section

Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid

Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection

Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

Indications

Premier choix

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Acute malnutrition in infants, children or adolescents (uncomplicated) [children]

Acute malnutrition in infants, children or adolescents (complicated) [children]

Acute pharyngitis

Chronic obstructive pulmonary disease with acute exacerbation

Periapical abscess without sinus

Acute otitis media

Acute sinusitis

co-prescrire avec gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescrire avec gentamicin

Sepsis without septic shock

Second choix

Bacterial meningitis

Autres indications

Infectious cystitis

Bacterial infection of unspecified site

Amoxicillin + clavulanic acid

Section

Access group antibiotics

Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection

Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid

Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Antituberculosis medicines

Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

Premier choix

Peritoneal abscess (mild-moderate)

Neutropenia (low-risk)

Other specified pneumonia (Hospital-acquired pneumonia)

Infectious cystitis

Chronic obstructive pulmonary disease with acute exacerbation

Peritonitis (mild-moderate)

Acute sinusitis

Bacterial cellulitis, erysipelas or lymphangitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choix

Osteomyelitis or osteitis

Acute otitis media

Other specified prophylactic measures

Bacterial infection of joint

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

co-prescrire avec clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

Autres indications

Bacterial infection of unspecified site

Multi-drug resistant Mycobacterium tuberculosis

Ampicillin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension

Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

Premier choix

co-prescrire avec [gentamicin](#)

Peritoneal abscess (severe)

co-prescrire avec [gentamicin](#)

Sepsis without septic shock

co-prescrire avec [gentamicin](#)

Peritoneal abscess (mild-moderate)

co-prescrire avec [gentamicin](#)

Peritonitis (severe)

co-prescrire avec [gentamicin](#)

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescrire avec [gentamicin](#)

Peritonitis (mild-moderate)

co-prescrire avec [gentamicin](#)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choix

Bacterial meningitis

Autres indications

Bacterial infection of unspecified site

Azithromycin

Section

Watch group antibiotics

Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

Indications

Premier choix

Chlamydia trachomatis

Typhoid fever

Yaws

Paratyphoid fever

Cholera

Cholera [children]

Trachoma

co-prescrire avec ceftriaxone

Gonococcal infection

Second choix

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescrire avec cefixime

Gonococcal infection

Aztreonam

Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

Other specified bacterial diseases

Bedaquiline

Section

Antituberculosis medicines

Oral > Solid: 100 mg tablet; 20 mg tablet

Indications

Multi-drug resistant Mycobacterium tuberculosis

Benzathine benzylpenicillin

Section

Access group antibiotics

Parenteral > General injections > IM: 1.2 million IU in vial (\approx 900 mg) powder for injection; 2.4 million IU in vial (\approx 1.8 g) powder for injection

Indications

Premier choix

Syphilis

Congenital syphilis [children]

Autres indications

Bacterial infection of unspecified site

Benzylicillin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

Indications

Premier choix

Congenital syphilis [children]

Syphilis

co-prescrire avec gentamicin

Sepsis without septic shock

co-prescrire avec gentamicin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescrire avec gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Second choix

Bacterial meningitis

Autres indications

Bacterial infection of unspecified site

Capreomycin

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

Multi-drug resistant Mycobacterium tuberculosis

Cefalexin

Section

Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid: 250 mg (as monohydrate)

Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)

Oral > Solid > dispersible tablet: 125 mg; 250 mg

Indications

Premier choix

Bacterial cellulitis, erysipelas or lymphangitis

Second choix

Acute pharyngitis

Chronic obstructive pulmonary disease with acute exacerbation

Autres indications

Bacterial infection of unspecified site

Cefazolin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

Indications

Premier choix

Other specified prophylactic measures

co-prescrire avec metronidazole

Other specified prophylactic measures

Second choix

Osteomyelitis or osteitis

Bacterial infection of joint

Autres indications

Surgical site infection

Cefepime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

Indications

Other specified bacterial diseases

Cefiderocol

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Cefixime

Section

Watch group antibiotics

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

Indications

Second choix

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescrire avec azithromycin

Gonococcal infection

Cefotaxime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Indications

Premier choix

Other specified pneumonia (Hospital-acquired pneumonia)

Bacterial meningitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescrire avec amikacin

Inflammatory and other diseases of prostate (severe)

co-prescrire avec amikacin

Acute pyelonephritis (severe)

co-prescrire avec clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescrire avec metronidazole

Peritonitis (severe)

co-prescrire avec metronidazole

Peritonitis (mild-moderate)

co-prescrire avec metronidazole

Peritoneal abscess (severe)

co-prescrire avec metronidazole

Peritoneal abscess (mild-moderate)

Second choix

Osteomyelitis or osteitis

Bacterial infection of joint

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Sepsis without septic shock

Autres indications

Bacterial infection of unspecified site

Ceftaroline

Section

Reserve group antibiotics

Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

Indications

Other specified bacterial diseases

Ceftazidime

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

Indications

Premier choix

co-prescrire avec [vancomycin](#)

[Endophthalmitis](#)

Autres indications

[Pseudomonas aeruginosa resistant to other antibiotic](#)

Ceftazidime + avibactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)

[Carbapenem resistant Enterobacterales](#)

Ceftolozane + tazobactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

Indications

[Carbapenem-resistant Pseudomonas aeruginosa](#)

Ceftriaxone

Section

Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Indications

Premier choix

[Typhoid fever](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

[Paratyphoid fever](#)

[Other specified pneumonia \(Hospital-acquired pneumonia\)](#)

[Bacterial meningitis](#)

co-prescrire avec [amikacin](#)

[Acute pyelonephritis \(severe\)](#)

co-prescrire avec [amikacin](#)

[Inflammatory and other diseases of prostate \(severe\)](#)

co-prescrire avec [azithromycin](#)

[Gonococcal infection](#)

co-prescrire avec [clarithromycin](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\)](#)

co-prescrire avec metronidazole

Necrotising fasciitis

co-prescrire avec metronidazole

Peritonitis (mild-moderate)

co-prescrire avec metronidazole

Peritonitis (severe)

co-prescrire avec metronidazole

Peritoneal abscess (mild-moderate)

co-prescrire avec metronidazole

Peritoneal abscess (severe)

co-prescrire avec vancomycin

Endophthalmitis

Second choix

Bacterial infection of joint

Osteomyelitis or osteitis

Infectious gastroenteritis or colitis without specification of infectious agent

Sepsis without septic shock

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Autres indications

Bacterial infection of unspecified site

Cefuroxime

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

Indications

Second choix

Other specified prophylactic measures

Chloramphenicol

Section

Access group antibiotics

Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)

Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection

Oral > Liquid: 150 mg per 5 mL (as palmitate)

Oral > Solid: 250 mg capsule

Indications

Second choix

Bacterial meningitis

Autres indications

Bacterial infection of unspecified site

Ciprofloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 2 mg per mL (as hyclate)

Oral > Liquid: 250 mg per 5 mL (anhydrous)

Oral > Solid: 250 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

Indications

Premier choix

Neutropenia (low-risk)

Inflammatory and other diseases of prostate (mild to moderate)

Typhoid fever

Paratyphoid fever

Infectious gastroenteritis or colitis without specification of infectious agent

Acute pyelonephritis (mild to moderate)

Second choix

Cholera

Cholera [children]

co-prescrire avec metronidazole

Peritoneal abscess (mild-moderate)

co-prescrire avec metronidazole

Peritonitis (mild-moderate)

Autres indications

Bacterial infection of unspecified site

Clarithromycin

Section

Watch group antibiotics

Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Oral > Solid > dosage form: 500 mg; 250 mg

Oral > Solid > dosage form: 500 mg

Indications

Premier choix

co-prescrire avec cefotaxime

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescrire avec ceftriaxone

Bacterial pneumonia (Community-acquired pneumonia - severe)

Second choix

Acute pharyngitis

co-prescrire avec amoxicillin + clavulanic acid

Bacterial pneumonia (Community-acquired pneumonia - severe)

Autres indications

Helicobacter pylori associated gastric ulcer

Clindamycin

Section

Access group antibiotics

Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride) capsule

Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection

Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)

Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride)

Indications

Premier choix

co-prescrire avec piperacillin + tazobactam

Necrotising fasciitis

Second choix

Osteomyelitis or osteitis

Bacterial infection of joint

Autres indications

Bacterial infection of unspecified site

Clofazimine

Section

Antituberculosis medicines

Oral > Solid: 100 mg; 50 mg

Antileprosy medicines

Oral > Solid: 100 mg; 50 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Leprosy

Cloxacillin

Section

Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid

Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection

Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

Indications

Premier choix

Bacterial infection of joint

Osteomyelitis or osteitis

Bacterial cellulitis, erysipelas or lymphangitis

Second choix

co-prescrire avec amikacin

Sepsis without septic shock

Autres indications

Bacterial infection of unspecified site

Colistin (injection)

Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Cycloserine

Section

Antituberculosis medicines

Oral > Solid: 250 mg; 125 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Dapsone

Section

Antileprosy medicines

Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet

Indications

Leprosy

Daptomycin

Section

Reserve group antibiotics

Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection

Indications

Other specified bacterial diseases

Delafloxacin

Section

Watch group antibiotics

Parenteral > General injections > IV: 300 mg lyophilized powder for injection

Oral > Solid: 450 mg

Indications

Methicillin resistant *Staphylococcus aureus*

Delamanid

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 25 mg

Oral > Solid > tablet: 50 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Doxycycline

Section

Access group antibiotics

Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)

Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)

Oral > Solid > dispersible tablet: 100 mg (as monohydrate)

Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)

Oral > Solid > dosage form: 100 mg (as hyclate)

Indications

Premier choix

Chlamydia trachomatis

Cholera

Second choix

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Chronic obstructive pulmonary disease with acute exacerbation

Cholera [children]

Autres indications

Bacterial infection of unspecified site

Eravacycline

Section

Reserve group antibiotics

Parenteral > General injections > IV: 50 mg lyophilized powder for injection

Indications

Carbapenem resistant Enterobacterales

Erythromycin

Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)

Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)

Oral > Solid: 250 mg (as stearate or ethylsuccinate)

Indications

Second choix

Therapeutic equivalent to [clarithromycin](#) pour

Acute pharyngitis

Autres indications

Bacterial infection of unspecified site

Ethambutol

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

Indications

Other specified tuberculosis

Tuberculosis

Ethambutol + isoniazid

Section

Antituberculosis medicines

Oral > Solid: 400 mg + 150 mg tablet

Indications

Tuberculosis

Ethambutol + isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

Indications

Tuberculosis

Ethambutol + isoniazid + rifampicin

Section

Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 150 mg tablet

Indications

Tuberculosis

Ethionamide

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 125 mg

Oral > Solid > tablet: 250 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Tuberculous meningitis

Fifth generation cephalosporins

Section

Reserve group antibiotics

.

Indications

Other specified bacterial diseases

Flomoxef

Section

Watch group antibiotics

Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

Indications

Other specified other antibiotic resistant Enterobacterales

Fosfomycin (injection)

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Fourth generation cephalosporins

Section

Watch group antibiotics

.

Indications

Other specified bacterial diseases

Gatifloxacin

Section

Antituberculosis medicines

Oral > Solid: 200 mg; 400 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Gentamicin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

Indications

Premier choix

Neonatal meningitis

co-prescrire avec amoxicillin

Sepsis without septic shock

co-prescrire avec amoxicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescrire avec ampicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescrire avec ampicillin

Sepsis without septic shock

co-prescrire avec ampicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescrire avec ampicillin

Peritoneal abscess (severe)

co-prescrire avec ampicillin

Peritonitis (mild-moderate)

co-prescrire avec ampicillin

Peritonitis (severe)

co-prescrire avec ampicillin

Peritoneal abscess (mild-moderate)

co-prescrire avec benzylpenicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescrire avec benzylpenicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescrire avec benzylpenicillin

Sepsis without septic shock

Second choix

Other specified prophylactic measures

Gonococcal infection

Autres indications

Bacterial infection of unspecified site

Imipenem + cilastatin

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection

Antituberculosis medicines

Indications

Second choix

Therapeutic equivalent to meropenem pour

Neutropenia (high-risk)

Therapeutic equivalent to meropenem pour

Peritoneal abscess (severe)

Therapeutic equivalent to meropenem pour

Peritonitis (severe)

Autres indications

Pseudomonas aeruginosa resistant to other antibiotic

Antibiotic resistant Acinetobacter baumannii

Therapeutic equivalent to meropenem pour

Multi-drug resistant Mycobacterium tuberculosis

Imipenem + cilastatin + relebactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500 mg + 500 mg + 250 mg powder for injection

Indications

Other specified other antibiotic resistant Enterobacterales

Carbapenem resistant Enterobacterales

Carbapenem-resistant Pseudomonas aeruginosa

Isoniazid

Section

Antituberculosis medicines

Parenteral > General injections > IV: 100 mg per mL

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 100 mg; 300 mg

Indications

Other specified tuberculosis

Tuberculosis

Isoniazid + pyrazinamide + rifampicin

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg

Indications

Tuberculosis

Isoniazid + rifampicin

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 50 mg + 75 mg

Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg

Indications

Tuberculosis

Isoniazid + rifapentine

Section

Antituberculosis medicines

Oral > Solid: 300 mg + 300 mg tablet (scored)

Indications

Latent tuberculosis

Kanamycin (injection)

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg powder for injection (vial)

Indications

Multi-drug resistant Mycobacterium tuberculosis

Levofloxacin

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 250 mg; 500 mg; 750 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Linezolid

Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 mg per mL in 300 mL bag

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 400 mg tablet; 600 mg tablet

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 600 mg

Antituberculosis medicines

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 600 mg

Indications

Other specified bacterial diseases

Methicillin resistant Staphylococcus aureus

Vancomycin resistant Staphylococcus aureus

Vancomycin resistant Enterococcus

Multi-drug resistant Mycobacterium tuberculosis

Meropenem

Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Antituberculosis medicines

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

Indications

Second choix

Neutropenia (high-risk)

Peritoneal abscess (severe)

Peritonitis (severe)

Neonatal meningitis

Multi-drug resistant *Mycobacterium tuberculosis*

Meropenem + vaborbactam

Section

Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Carbapenem resistant *Acinetobacter baumannii*

Metronidazole

Section

Access group antibiotics

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Oral > Solid: 200 to 500 mg tablet

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial

Injection

Local > Rectal > Suppository: 500 mg; 1 g

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

Indications

Premier choix

Intestinal infections due to *Clostridioides difficile*

Trichomoniasis

co-prescrire avec cefazolin

Other specified prophylactic measures

co-prescrire avec cefotaxime

Peritonitis (severe)

co-prescrire avec cefotaxime

Peritonitis (mild-moderate)

co-prescrire avec cefotaxime

Peritoneal abscess (mild-moderate)

co-prescrire avec cefotaxime

Peritoneal abscess (severe)

co-prescrire avec ceftriaxone

Necrotising fasciitis

co-prescrire avec ceftriaxone

Peritonitis (severe)

co-prescrire avec ceftriaxone

Peritoneal abscess (mild-moderate)

co-prescrire avec ceftriaxone

Peritoneal abscess (severe)

co-prescrire avec ceftriaxone

Peritonitis (mild-moderate)

Second choix

co-prescrire avec ciprofloxacine

Peritonitis (mild-moderate)

co-prescrire avec ciprofloxacine

Peritoneal abscess (mild-moderate)

Autres indications

Bacterial infection of unspecified site

Moxifloxacin

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 400 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Tuberculosis

Nitrofurantoin

Section

Access group antibiotics

Oral > Liquid: 25 mg per 5 mL oral liquid

Oral > Solid > dosage form: 100 mg; 50 mg

Indications

Premier choix

Infectious cystitis

Ofloxacin

Section

Antituberculosis medicines

Oral > Solid: 200 mg; 400 mg

Indications

Multi-drug resistant Mycobacterium tuberculosis

Omadacycline

Section

Reserve group antibiotics

Parenteral > General injections > IV: 100 mg lyophilized powder for injection

Oral > Solid: 300 mg

Indications

Methicillin resistant Staphylococcus aureus

Oxazolindinones

Section

Reserve group antibiotics

.

Indications

Other specified bacterial diseases

P-aminosalicylate sodium

Section

Antituberculosis medicines

Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid) powder for oral solution

Indications

Multi-drug resistant Mycobacterium tuberculosis

P-aminosalicylic acid

Section

Antituberculosis medicines

Oral > Solid: 4 g granules in sachet

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Phenoxyethylpenicillin

Section

Access group antibiotics

Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid

Oral > Solid: 250 mg (as potassium salt) tablet

Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

Indications

Premier choix

Acute pharyngitis

Periapical abscess without sinus

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Autres indications

Bacterial infection of unspecified site

Piperacillin + tazobactam

Section

Watch group antibiotics

Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

Indications

Premier choix

Peritoneal abscess (severe)

Other specified pneumonia (Hospital-acquired pneumonia)

Neutropenia (high-risk)

Peritonitis (severe)

co-prescrire avec clindamycin

Necrotising fasciitis

Plazomicin

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500 mg per 10 mL

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Polymyxin B (injection)

Section

Reserve group antibiotics

Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Polymyxins

Section

Reserve group antibiotics

Indications

Other specified bacterial diseases

Pretomanid

Section

Antituberculosis medicines

Oral > Solid > tablet: 200 mg

Indications

Multi-drug resistant *Mycobacterium tuberculosis*

Procaine benzylpenicillin

Section

Access group antibiotics

Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

Indications

Premier choix

Congenital syphilis [children]

Second choix

Syphilis

Protionamide

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to ethionamide pour

Multi-drug resistant *Mycobacterium tuberculosis*

Pyrazinamide

Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 400 mg; 500 mg

Indications

Tuberculosis

Rifabutin

Section

Antituberculosis medicines

Oral > Solid: 150 mg

Indications

Tuberculosis

Rifampicin

Section

Antituberculosis medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

Parenteral > General injections > IV: 600 mg in vial powder for injection

Antileprosy medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

Indications

Tuberculosis

Other specified tuberculosis

Leprosy

Rifapentine

Section

Antituberculosis medicines

Oral > Solid > tablet: 150 mg; 300 mg

Indications

Tuberculosis

Latent tuberculosis

Spectinomycin

Section

Access group antibiotics

Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection

Indications

Second choix

Gonococcal infection

Autres indications

Bacterial infection of unspecified site

Streptomycin (injection)

Section

Antituberculosis medicines

Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial

Indications

Multi-drug resistant Mycobacterium tuberculosis

Sulfamethoxazole + trimethoprim

Section

Access group antibiotics

Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule

Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid

Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet

Oral > Solid > dispersible tablet: 100 mg + 20 mg

Indications

Premier choix

Infectious cystitis

Second choix

Infectious gastroenteritis or colitis without specification of infectious agent

Autres indications

Bacterial infection of unspecified site

Tedizolid

Section

Reserve group antibiotics

Indications

Therapeutic equivalent to linezolid pour

Methicillin resistant Staphylococcus aureus

Therapeutic equivalent to linezolid pour

Vancomycin resistant Staphylococcus aureus

Therapeutic equivalent to linezolid pour

Vancomycin resistant Enterococcus

Terizidone

Section

Antituberculosis medicines

Indications

Therapeutic equivalent to cycloserine pour

Multi-drug resistant Mycobacterium tuberculosis

Tetracycline

Section

Access group antibiotics

Oral > Solid: 250 mg (hydrochloride)

Indications

Bacterial infection of unspecified site

Tigecycline

Section

Reserve group antibiotics

Parenteral > General injections > IV: 50 mg in vial powder for injection

Indications

Other specified bacterial diseases

Trimethoprim

Section

Access group antibiotics

Oral > Liquid: 50 mg per mL

Oral > Solid: 100 mg; 200 mg

Indications

Premier choix

Infectious cystitis

Vancomycin

Section

Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection

Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Indications

Premier choix

Necrotising fasciitis

co-prescrire avec ceftazidime

Endophthalmitis

co-prescrire avec ceftriaxone

Endophthalmitis

Second choix

Neutropenia (high-risk)

Intestinal infections due to Clostridioides difficile

Autres indications

Methicillin resistant Staphylococcus aureus